Rituximab for the treatment of acute exacerbation of interstitial lung disease associated with connective tissue disease.
RMD Open
; 9(3)2023 09.
Article
em En
| MEDLINE
| ID: mdl-37673443
ABSTRACT
BACKGROUND:
Acute exacerbation of interstitial lung disease (AE-ILD) is a severe complication with a poor prognosis. No clinical trials have supported the use of rituximab in AE-ILD associated with connective tissue disease.METHODS:
We present a series of four cases in which administration of rituximab was associated with appropriate clinical, radiological and functional progress.RESULTS:
The four patients were alive 30 days after discharge following their exacerbation.CONCLUSIONS:
Given the speed of action, safety and efficacy profile observed for rituximab, we believe that this agent should be further investigated in clinical trials so that it could be included in the daily clinical management of this severe condition.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Doenças Pulmonares Intersticiais
/
Doenças do Tecido Conjuntivo
Tipo de estudo:
Diagnostic_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Humans
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article